Drugs have landed GlaxoSmithKline Plc (LSE, NYSE: GSK) in the docket, again. Two years ago it was securities fraud claims surrounding Paxil - in the UK marketed under the name Seroxat - two weeks ago it was the drug Avandia. See the 2005 action’s press release and the 2007 action’s complaint (07 Civ. 5574, SDNY).
The current status of the earlier action, In re GlaxoSmithKline Sec. Litig. (05 Civ. 3751, SDNY) filed in May 2005, is that the second amended complaint was dismissed in October 2006: “Plaintiff has failed to state a primary violation of the securities laws under section 10(b). Without a primary violation, there can be no secondary, or derivative, violation under Section 20(a). Accordingly, Plaintiff’s Section 20(a) claim is also dismissed.” (cited in In re NTL Sec. Litig.) An appeal had been filed with the US Court of Appeals for the Second Circuit. (Also see GSK’s 2006 Annual Report, p.163 (165 of 192).)
After having read the complaint in the current action (filed 11 June), for more information see the following GSK communications:
press release in response to New England Journal of Medicine editorials (5 June)
press release regarding data from RECORD study in relation to Avandia (5 June)
statement of Moncef Slaoui, PhD, GSK Chairman Research & Development in testimony before the House Committee on Oversight and Government Reform (6 June)
A GSK spokesperson has, in line with its policy not to comment on individual lawsuits, submitted the following in response to a request for comment concerning the current action:
We will vigorously defend our medicine. GSK has acted responsibly, transparently and with the best interest of patients in mind. Any fair examination of the company?s record will show that GSK has been transparent in its efforts to thoroughly study the safety and effectiveness of Avandia, and to widely communicate that information to governments, regulatory authorities, scientific peers, physicians and others in a variety of ways.
The proposed Class Period is the period between 27 October 2005 and 21 May 2007, inclusive. The deadline to apply for Lead Plaintiff status is 10 August 2007.
Avandia Heart Attack: Questions Still Remain Washington, DC: The Avandia debacle continues to daze and confuse in the face of conflicting information. GlaxoSmithKline (Glaxo), the makers of Avandia, continue to claim that studies conclude there is no risk of Avandia heart attack...
Near Death Experience on Avandia Galvaston, TX: Otis is a coach and teacher at a high school in Texas. He was put on Avandia for his diabetes approximately five years ago. In the fall of 2006 he was hospitalized for a heart attack, possibly an Avandia heart attack...
Avandia Experiment may have Killed Mom Memphis, TN: When Sharon's mom first started taking Avandia for her diabetes, the drug was still experimental. Now, Sharon's mom is dead from congestive heart failure and Sharon herself is worried, after having taken Avandia for more than a year for her own diabetes.
Did Avandia Kill A 38-Year Old Mother of Two Arlington, TN: One November morning in 2007 Wendy, a 38-year old mother of two, was found dead from a heart attack. She was a diabetic, and had been taking Avandia for several months...
Avandia Roundup: Sales Drop, GlaxoSmithKline Cut Jobs Washington, DC: A diabetes drug known to contribute to heart complications, fluid retention and weight gain continues to fall from its once-lofty perch. Avandia was at one time a giant in the treatment of Type 2 diabetes, but has fallen on hard times as more and more physicians move their patients away from Avandia, to alternative diabetes drugs that carry less risk.